

Supporting Information

for

Convergent synthesis of a tetrasaccharide repeating unit of the *O*-specific polysaccharide from the cell wall lipopolysaccharide of *Azospirillum brasilense* strain Sp7


Pintu Kumar Mandal,^{*1} Debashis Dhara² and Anup Kumar Misra²

Address:¹Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, BS-10/1, Sector 10, Jankipuram extension, Sitapur Road, Lucknow, 226 031, India and ²Bose Institute, Division of Molecular Medicine, P-1/12, C.I.T. Scheme VII-M, Kolkata-700054, India


E-mail: Pintu Kumar Mandal - pintuchem06@gmail.com

*Corresponding author


1D and 2D NMR spectra of compounds **1, 2, 7, 8, 9, 10**




^1H , ^{13}C and DEPT 135 NMR spectra of 2-aminoethyl (α -L-fucopyranosyl)-(1 \rightarrow 4)-(2-acetamido-2-deoxy- β -D-glucopyranoside)-(1 \rightarrow 3)-(α -L-rhamnopyranosyl)-(1 \rightarrow 3)- β -D-galactopyranoside (**1**) (D_2O).




2D COSY and HSQC NMR spectra (selected regions) of 2-aminoethyl (α -L-fucopyranosyl)-(1 \rightarrow 4)-(2-acetamido-2-deoxy- β -D-glucopyranoside)-(1 \rightarrow 3)-(α -L-rhamnopyranosyl)-(1 \rightarrow 3)- β -D-galactopyranoside (**1**) (D_2O).





¹H, ¹³C and DEPT 135 NMR spectra of 2-azidoethyl 2,4,6-tri-O-acetyl-β-D-galactopyranoside (**2**) (CDCl₃ + CCl₄).




^1H , ^{13}C and DEPT 135 NMR spectra of 2-azidoethyl 2,6-di-*O*-acetyl- β -D-galactopyranoside (**7**) ($\text{CDCl}_3 + \text{CCl}_4$).





^1H , ^{13}C and DEPT 135 NMR spectra of 2-azidoethyl (2-*O*-acetyl-4-*O*-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-acetyl- β -D-galactopyranoside (**8**) ($\text{CDCl}_3 + \text{CCl}_4$).




2D COSY and HSQC NMR spectra (selected regions) of 2-azidoethyl (2-*O*-acetyl-4-*O*-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-acetyl- β -D-galactopyranoside (**8**) ($\text{CDCl}_3 + \text{CCl}_4$).




¹H, ¹³C and DEPT 135 NMR spectra of ethyl (2,3,4-tri-*O*-benzyl- α -L-fucopyranosyl)-(1 \rightarrow 4)-3-*O*-acetyl-6-*O*-benzyl-2-deoxy-2-phthalimido-1-thio- β -D-glucopyranoside (**9**) (CDCl₃ + CCl₄).



2D COSY and HSQC NMR spectra (selected regions) of ethyl (2,3,4-tri-*O*-benzyl- α -L-fucopyranosyl)-(1 \rightarrow 4)-3-*O*-acetyl-6-*O*-benzyl-2-deoxy-2-phthalimido-1-thio- β -D-glucopyranoside (**9**) ($\text{CDCl}_3 + \text{CCl}_4$).



¹H, ¹³C and DEPT 135 NMR spectra of 2-azidoethyl (2,3,4-tri-O-benzyl- α -L-fucopyranosyl)-(1 \rightarrow 4)-(3-O-acetyl-6-O-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranoside)-(1 \rightarrow 3)-(2-O-acetyl-4-O-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-O-acetyl- β -D-galactopyranoside (**10**) (CDCl₃ + CCl₄).



2D COSY and HSQC NMR spectra (selected regions) of 2-azidoethyl (2,3,4-tri-*O*-benzyl- α -L-fucopyranosyl)-(1 \rightarrow 4)-(3-*O*-acetyl-6-*O*-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranoside)-(1 \rightarrow 3)-(2-*O*-acetyl-4-*O*-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-acetyl- β -D-galactopyranoside (**10**) ($\text{CDCl}_3 + \text{CCl}_4$).